Fludarabine
Multiple Sclerosis, Secondary Progressive
Indapta Therapeutics, INC.Small moleculePhase 1Active
CC
43/ 100
Provisional rating · Methodology v0.2
Rating breakdown
- Clinical Evidence
- 28/ 100
- Competitive Position
- 89/ 100
Competitive context
11 Active assets in the Multiple Sclerosis, Secondary Progressive cohort.
| Asset / Sponsor | Phase | Rating |
|---|---|---|
Masitinib AB Science | Phase 3 | B |
Kyv-101 Kyverna Therapeutics | Phase 2 | B |
2-BUTENEDIOIC ACID, (2E)-, DIMETHYL ESTER Biogen | Phase 3 | B |
Ibudilast MediciNova | Phase 2 | B |
Cladribine University Hospital, Strasbourg, France | Phase 2/3 | B |
View all 23 →
Same molecule, other indications
Fludarabine is also rated in:
acute myeloid leukemia with abnormal bone marrow eosinophils inv(16)(p13q22) or t(16;16)(p13;q22)Dormant
BBB
Indicative ·
76 / 100
View asset →Are you the sponsor?
Submit your data room for a Verified Rating. The public-data rating remains visible alongside.
Contact →